by Peter Ciszewski | Sep 15, 2021
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of zanubrutinib (Brukinsa) to treat adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. MZL is a group of...
by Peter Ciszewski | Sep 14, 2021
Clete A. Kushida, MD, PhD, Neurologist and Division Chief and Medical Director of Stanford Sleep Medicine Center, explains how sleep is measured in clinical trials such as the REST-ON study, a double-blind, randomized, placebo-controlled phase 3 trial assessing...
by Peter Ciszewski | Sep 10, 2021
Saad Usmani, MD, FACP, Division Chief of Plasma Cell Disorders and Director of Clinical Research in Hematological Malignancies at Levine Cancer Institute, discusses follow-up data from the CARTITUDE-1 trial presented at ASCO 2021. Multiple myeloma is a blood...
by Peter Ciszewski | Sep 9, 2021
Sima Rozati, MD, Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine, discusses current treatment options for cutaneous T-cell lymphoma (CTCL). CTCL belongs to the non-Hodgkin lymphoma family as a rare group of malignancies....
by Peter Ciszewski | Sep 2, 2021
Richard Lafayette, MD, FACP, Director of the Stanford Glomerular Disease Center, Editor-in-Chief of ASN Kidney News, and Rheumatologist at Stanford Health Care, describes the patient population for immunoglobulin A (IgA) nephropathy. IgA nephropathy, also...
